Microbot Medical (MBOT) Upgraded at ValuEngine

Microbot Medical (NASDAQ:MBOT) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued on Friday.

Separately, Ladenburg Thalmann Financial Services started coverage on shares of Microbot Medical in a research report on Wednesday. They set a “buy” rating and a $1.75 price objective on the stock.

Microbot Medical (NASDAQ:MBOT) traded down $0.04 during trading on Friday, hitting $1.04. 1,212,724 shares of the stock traded hands, compared to its average volume of 832,689. The stock has a market cap of $40.15, a PE ratio of -1.51 and a beta of -0.39. Microbot Medical has a 12-month low of $1.00 and a 12-month high of $9.94.

In other news, Director Yoseph Bornstein sold 45,000 shares of the firm’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $1.21, for a total transaction of $54,450.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 272,990 shares of company stock worth $291,894. Corporate insiders own 31.83% of the company’s stock.

A hedge fund recently raised its stake in Microbot Medical stock. Vanguard Group Inc. grew its stake in shares of Microbot Medical Inc (NASDAQ:MBOT) by 252.2% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 159,992 shares of the biotechnology company’s stock after buying an additional 114,561 shares during the quarter. Vanguard Group Inc. owned 0.43% of Microbot Medical worth $228,000 at the end of the most recent quarter. Institutional investors and hedge funds own 4.67% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/02/04/microbot-medical-mbot-upgraded-at-valuengine.html.

Microbot Medical Company Profile

Microbot Medical Inc, formerly StemCells, Inc, is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply